Total Payments
$138,138
2024 Payments
$38,450
Companies
44
Transactions
756
Medicare Patients
8,004
Medicare Billing
$761,819
Payment Breakdown by Category
Other$105,638 (76.5%)
Food & Beverage$12,449 (9.0%)
Travel$10,624 (7.7%)
Research$9,000 (6.5%)
Gifts$300.00 (0.2%)
Education$127.14 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $105,638 | 42 | 76.5% |
| Food and Beverage | $12,449 | 674 | 9.0% |
| Travel and Lodging | $10,624 | 33 | 7.7% |
| Unspecified | $9,000 | 3 | 6.5% |
| Gift | $300.00 | 1 | 0.2% |
| Education | $127.14 | 3 | 0.1% |
Payments by Type
General
$129,138
753 transactions
Research
$9,000
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $101,359 | 176 | $0 (2024) |
| ABBVIE INC. | $11,193 | 179 | $0 (2024) |
| Madrigal Pharmaceuticals | $9,858 | 13 | $0 (2024) |
| Bausch Health US, LLC | $9,000 | 3 | $0 (2018) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $1,457 | 108 | $0 (2024) |
| Intercept Pharmaceuticals, Inc. | $818.12 | 48 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $541.92 | 36 | $0 (2024) |
| Merck Sharp & Dohme LLC | $411.81 | 25 | $0 (2024) |
| Intra-Sana Laboratories | $357.08 | 3 | $0 (2023) |
| Janssen Biotech, Inc. | $321.92 | 16 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $38,450 | 149 | Gilead Sciences, Inc. ($26,778) |
| 2023 | $22,415 | 129 | Gilead Sciences, Inc. ($11,959) |
| 2022 | $15,451 | 118 | Gilead Sciences, Inc. ($13,546) |
| 2021 | $3,464 | 91 | Gilead Sciences, Inc. ($2,214) |
| 2020 | $6,522 | 36 | Gilead Sciences, Inc. ($6,187) |
| 2019 | $9,410 | 65 | Gilead Sciences, Inc. ($8,607) |
| 2018 | $26,120 | 81 | Gilead Sciences, Inc. ($16,614) |
| 2017 | $16,306 | 87 | Gilead Sciences Inc ($15,452) |
All Payment Transactions
756 individual payment records from CMS Open Payments — Page 1 of 31
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $13.43 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 12/19/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $13.27 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 12/18/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $24.97 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/16/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/16/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $144.23 | General |
| Category: LIVER DISEASE | ||||||
| 12/16/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $17.87 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/12/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $18.65 | General |
| Category: Rare Disease | ||||||
| 12/09/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $27.02 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/05/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $20.35 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/04/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $7.86 | General |
| Category: IMMUNOLOGY | ||||||
| 11/27/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Education | In-kind items and services | $74.99 | General |
| Category: Immunology | ||||||
| 11/26/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.59 | General |
| 11/22/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $21.60 | General |
| Category: Immunology | ||||||
| 10/31/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $13.37 | General |
| Category: Gastroenterology | ||||||
| 10/28/2024 | Takeda Pharmaceuticals U.S.A., Inc. | EOHILIA (Drug) | Food and Beverage | In-kind items and services | $12.14 | General |
| Category: INTERNAL MEDICINE | ||||||
| 10/24/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,940.00 | General |
| Category: INFLAM | ||||||
| 10/24/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $19.03 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/21/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.80 | General |
| 10/19/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $12.97 | General |
| Category: VIROLOGY | ||||||
| 10/17/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Food and Beverage | In-kind items and services | $97.31 | General |
| Category: INFLAM | ||||||
| 10/16/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $21.72 | General |
| Category: THERAPY FOR CSID | ||||||
| 10/10/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,940.00 | General |
| Category: INFLAM | ||||||
| 10/08/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Travel and Lodging | In-kind items and services | $69.68 | General |
| Category: HCV | ||||||
| 10/08/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $15.17 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 10/07/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: INFLAM | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Dispersion SSD Tablets Plus Lactulose and Rifaximin Extended Intestinal Release EIR Tablets Plus Lactulose For the Treatment of Overt Hepatic Encephalopathy OHE. | Bausch Health US, LLC | $9,000 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 1,448 | 6,663 | $1.0M | $244,282 |
| 2022 | 22 | 1,766 | 1,961 | $740,914 | $151,365 |
| 2021 | 26 | 2,315 | 2,856 | $885,268 | $181,964 |
| 2020 | 26 | 2,475 | 2,981 | $917,196 | $184,208 |
Total Patients
8,004
Total Services
14,461
Medicare Billing
$761,819
Procedure Codes
95
All Medicare Procedures & Services
95 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3380 | Injection, vedolizumab, 1 mg | Office | 2023 | 12 | 5,100 | $306,000 | $88,140 | 28.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 243 | 318 | $47,700 | $27,395 | 57.4% |
| 45384 | Removal of polyps or growths of large bowel using a flexible endoscope with electrical cautery | Facility | 2023 | 125 | 125 | $131,250 | $19,619 | 14.9% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 73 | 76 | $85,500 | $13,998 | 16.4% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 83 | 84 | $75,180 | $13,693 | 18.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 118 | 118 | $27,140 | $12,879 | 47.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 161 | 179 | $18,795 | $10,500 | 55.9% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 135 | 137 | $109,600 | $9,379 | 8.6% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 60 | 60 | $53,700 | $9,343 | 17.4% |
| 43248 | Insertion of guide wire with dilation of esophagus using a flexible endoscope | Facility | 2023 | 57 | 58 | $35,960 | $6,566 | 18.3% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 66 | 67 | $38,860 | $5,193 | 13.4% |
| 76981 | Ultrasound scan of organ tissue for measuring elasticity | Office | 2023 | 67 | 67 | $15,544 | $4,981 | 32.0% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 33 | 33 | $29,535 | $4,160 | 14.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 43 | 43 | $8,385 | $4,140 | 49.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 45 | 69 | $7,590 | $4,100 | 54.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 46 | 46 | $6,900 | $3,343 | 48.5% |
| 45388 | Destruction of polyp or growth of large bowel using a flexible endoscope | Facility | 2023 | 14 | 14 | $16,450 | $2,917 | 17.7% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 16 | 16 | $15,680 | $1,832 | 11.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 20 | 22 | $4,510 | $983.84 | 21.8% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 14 | 14 | $2,030 | $879.34 | 43.3% |
| 91200 | Measurement of liver stiffness | Office | 2023 | 17 | 17 | $1,428 | $241.73 | 16.9% |
| 45384 | Removal of polyps or growths of large bowel using a flexible endoscope with electrical cautery | Facility | 2022 | 182 | 183 | $192,150 | $28,593 | 14.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 309 | 371 | $38,955 | $21,497 | 55.2% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 90 | 90 | $80,550 | $15,337 | 19.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 147 | 181 | $27,150 | $14,745 | 54.3% |
About Dr. John Phillips, MD
Dr. John Phillips, MD is a Gastroenterology healthcare provider based in Tupelo, Mississippi. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1023077732.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Phillips, MD has received a total of $138,138 in payments from pharmaceutical and medical device companies, with $38,450 received in 2024. These payments were reported across 756 transactions from 44 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($105,638).
As a Medicare-enrolled provider, Phillips has provided services to 8,004 Medicare beneficiaries, totaling 14,461 services with total Medicare billing of $761,819. Data is available for 4 years (2020–2023), covering 95 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Tupelo, MS
- Active Since 03/21/2006
- Last Updated 03/06/2025
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1023077732
Products in Payments
- Epclusa (Drug) $63,096
- REZDIFFRA (Drug) $9,858
- MAVYRET (Drug) $9,236
- RIFAXIMIN (Drug) $9,000
- Livdelzi (Drug) $8,902
- Vosevi (Drug) $4,074
- XIFAXAN (Drug) $1,003
- OCALIVA (Drug) $741.10
- RINVOQ (Biological) $523.46
- HUMIRA (Biological) $431.31
- DUPIXENT (Biological) $398.26
- TRULANCE (Drug) $395.88
- ENTYVIO (Biological) $364.30
- RELTONE 200 MG (Drug) $357.08
- Humira (Biological) $304.68
- STELARA (Biological) $264.96
- ZEPATIER (Drug) $199.33
- DIFICID (Drug) $196.82
- LINZESS (Drug) $182.74
- INJECTAFER (Drug) $169.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Tupelo
Stephen Amann, Md, MD
Gastroenterology — Payments: $12,665
Gastroenterology $12,665
Christopher Decker, Md, MD
Gastroenterology — Payments: $7,149
Gastroenterology $7,149
William Ogg, Md, MD
Gastroenterology — Payments: $4,695
Gastroenterology $4,695
Roger Huey, Md, MD
Gastroenterology — Payments: $4,116
Gastroenterology $4,116
Dr. Noel Hunt, M.d, M.D
Gastroenterology — Payments: $2,912
Gastroenterology $2,912
William Stone, M.d, M.D
Gastroenterology — Payments: $2,829
Gastroenterology $2,829